What Is NAD+? Benefits, Function & Why It Declines With Age (2026)

Key Takeaways

• NAD+ participates in more than 500 enzymatic reactions, making it one of the most used molecules in human metabolism.
• Three enzyme families (sirtuins, PARPs, and CD38) consume NAD+ during their work, which means your body is constantly burning through its supply.
• Human data on NAD+ and age are mixed: NAD+ was lower with age in skin and plasma studies, but a 2026 study across seven cohorts found whole-blood NAD+ stable with age.
• Oral NMN and NR (two NAD+ precursors) approximately doubled whole-blood NAD+ after 14 days at 1,000 mg/day in a 2026 human trial.
• Despite strong preclinical results, the 2026 PRISMA systematic review of 33 human intervention studies found that clinical outcomes beyond NAD+ elevation remain "heterogeneous and often null."

🩺 Doctor's Clinical Note

Dr. Jill Palko, MD, FACOG Cleveland Clinic-Trained · Board-Certified OB/GYN NPI #1093033011 · View Credentials

"NAD+ is an essential molecule in your cells that helps produce energy and repair DNA, but its levels naturally decline as you age. While NAD+ supplements can successfully raise the amount of NAD+ in your blood, human clinical trials have not yet proven that they provide noticeable anti-aging or health benefits."

💊 Pharmacist's Note

Aubrey Patterson, PharmD, BCACP Board-Certified Ambulatory Care Pharmacist BCACP #6153963 · NPI #1548782121 · View Credentials

"NAD+ is important for energy production and several other functions in the body, and research on NMN as a way to support NAD+ levels is encouraging. While early human studies show NMN can increase NAD+ levels, the evidence for broader benefits such as healthy aging and cognition is still developing."

Reviewed for clinical accuracy · September 2026

What Does NAD+ Stand For?

NAD stands for nicotinamide adenine dinucleotide. The "+" sign refers to its oxidized form. That means it's the version of the molecule that's ready to accept electrons. When it picks up those electrons, it becomes NADH (the reduced form). This back-and-forth between NAD+ and NADH is what drives energy production inside your mitochondria.

You'll see the terms NAD, NAD+, and NAD Plus used interchangeably online. They all describe the same molecule. In scientific papers, NAD+ specifically means the oxidized form. In everyday health conversations, people just say "NAD" and mean the same thing.

One point that trips people up: NAD+ is not a vitamin, though it's built from vitamin B3. Your body manufactures NAD+ from three B3 variants: nicotinamide (NAM), nicotinic acid (NA, also called niacin), and nicotinamide riboside (NR). A fourth precursor, nicotinamide mononucleotide (NMN), sits one step closer to NAD+ in the production chain. More on each of those later.

What Does NAD+ Actually Do in the Body?

NAD+ has two main jobs in the body. It carries electrons from the food you break down to the mitochondrial electron transport chain, where they generate ATP. It also fuels signaling enzymes, including sirtuins that regulate gene expression and PARPs that repair DNA damage. More than 500 enzymatic reactions depend on it.

Job one: electron shuttle. Inside your mitochondria, NAD+ picks up electrons from the food you break down (glucose, fatty acids, amino acids) and delivers them to the electron transport chain, where those electrons generate ATP. No NAD+, no electron delivery, no ATP. This is first-semester biochemistry, and it's been textbook knowledge since the 1930s. A 2021 review in Molecular Metabolism cataloged more than 500 enzymatic reactions that require NAD+ as a cofactor (Amjad et al., 2021).

Job two: signal and sacrifice. Three families of enzymes don't just use NAD+. They destroy it as part of their work:

Sirtuins (SIRT1–SIRT7) are deacetylases. They strip acetyl tags from proteins to regulate gene expression, mitochondrial function, and inflammation. Each reaction consumes one molecule of NAD+. SIRT1 and SIRT3 get the most attention in aging research. SIRT1 matters because it influences metabolism and stress resistance in the nucleus. SIRT3 matters because it controls mitochondrial protein acetylation. When NAD+ is low, sirtuin activity drops, and downstream metabolic regulation suffers.

PARPs (PARP1, PARP2) are DNA repair enzymes. When your DNA breaks from UV exposure, oxidative stress, or normal replication errors, PARP1 burns through large quantities of NAD+ to build poly(ADP-ribose) chains that flag the break site and recruit repair proteins. A single strand break can consume hundreds of NAD+ molecules. This matters more as you age because DNA damage accumulates, PARP activity increases, and the NAD+ drain accelerates.

CD38 is an ectoenzyme found on the surface of immune cells. It hydrolyzes NAD+ into nicotinamide and ADP-ribose. CD38 has become the star of aging research since a landmark 2016 paper in Cell Metabolism showed that CD38 protein levels rise with age across multiple tissues, and that this increase, not a decrease in NAD+ production, is the primary driver of age-related NAD+ decline in mice (Camacho-Pereira et al., 2016). Mice lacking the CD38 gene maintained youthful NAD+ levels well into old age.

A quick note on scale. Your body contains roughly 3 grams of NAD+ at any given time. That doesn't sound like much, but the turnover rate is staggering: your cells recycle and rebuild their entire NAD+ pool multiple times per day. One estimate puts the daily NAD+ flux at around 400 to 500 mg, meaning the molecule is built, used, broken down, and rebuilt continuously. When researchers talk about NAD+ "declining," they mean the steady-state level is dropping because destruction is outpacing this recycling loop. So your body is running two operations simultaneously: it needs NAD+ to make energy, and it needs NAD+ to repair damage and regulate genes. Both operations accelerate their NAD+ consumption as you age. That's the tension at the center of every NAD+ conversation.

Why Do NAD+ Levels Decline With Age?

In tissues where NAD+ falls with age, the leading explanation is that the body breaks NAD+ down faster than it makes it: consuming enzymes such as CD38 and PARPs become more active as DNA damage and inflammation rise. How much it falls depends on the tissue and how it is measured.

NAD+ was lower with age in skin samples (Massudi et al., 2012) and in plasma (Clement et al., 2019), while whole-blood NAD+ stayed stable with age across seven cohorts (Trętowicz et al., 2026).

Massudi et al. (2012) measured NAD+ in skin samples from 49 surgical patients (newborns and adults aged 15 to 77). NAD+ was negatively correlated with age in both males and females, and in males the drop tracked with rising DNA damage and PARP activity. A later study by Clement et al. (2019) measured plasma from healthy adults aged 20 to 87 and found lower NAD+, NADP+, and related metabolites in older age groups.

The "how much" question gets asked constantly. The number you'll see cited most often is a 50% decline by middle age, sometimes "up to 80%." Those figures don't hold up as universal numbers: they mix different tissues, age ranges, and reference points, and the human studies behind them are small. Massudi's skin data showed a correlation between age and lower NAD+, not a fixed percentage for everyone, and Clement's plasma study compared age groups at a single point in time. A 2026 study in Nature Metabolism measured whole-blood NAD+ with a validated mass-spectrometry method across seven independent cohorts and found levels remained stable with age and across lifestyle interventions, while rising as expected with NR supplementation (Trętowicz et al., 2026). The honest answer is that NAD+ changes with age appear to differ by tissue and measurement method, and no single decline rate applies to everyone.

Three mechanisms drive the decline:

Rising CD38 expression. Chronic low-grade inflammation ("inflammaging") triggers senescent cells to release inflammatory cytokines. Those cytokines attract M1-like macrophages into fat tissue and the liver. These macrophages express high levels of CD38, which chews through local NAD+ stores. A 2020 paper in Nature Metabolism traced this causal chain: senescent cells → inflammatory signals → CD38-high macrophages → tissue NAD+ depletion (Covarrubias et al., 2020). This is probably the most significant finding in the NAD+ aging story of the past decade.

Increased PARP activity. DNA damage accumulates. PARP1 works overtime to fix it. Each repair event consumes NAD+. By your 60s and 70s, PARP is burning through substantially more NAD+ per day than it did in your 20s.

Reduced biosynthesis efficiency. The enzymes that build NAD+, particularly NAMPT (nicotinamide phosphoribosyltransferase, the rate-limiting enzyme in the salvage pathway), show reduced expression in aged tissues. So production slows while consumption accelerates.

A nuance worth flagging: a 2022 review in Nutrients (Peluso et al., 2022) examined NAD+ decline data across yeast, C. elegans, rats, mice, monkeys, and humans and concluded that "despite systematic claims of overall changes in NAD+ levels with aging, the evidence to support such claims is very limited and often restricted to a single tissue or cell type." Declines have been reported in specific tissues, the blood data now conflict, and we still lack large longitudinal human studies tracking NAD+ across the full body over time. Most of the strongest data comes from mice.

What Are the Benefits of NAD+?

NAD+ itself is not a supplement you swallow for a specific "benefit" the way you'd take ibuprofen for a headache. It's a molecule your body already makes and uses. The question people are really asking is: what happens when you raise NAD+ levels back up, and does it actually help?

Here's what the evidence says as of 2026, broken into categories.

What NAD+ effects are well established in humans?

Two things are well established in humans: oral NMN and NR raise blood NAD+, roughly doubling whole-blood NAD+ after 14 days at 1,000 mg/day in one 2026 trial, and both were generally well tolerated in short-term studies. Their effects on health outcomes are much less consistent.

Oral NMN and NR raise blood NAD+ levels. A January 2026 head-to-head human trial run by Nestlé Research (Christen et al., 2026) comparing NMN, NR, and nicotinamide found that in 65 healthy adults, 1,000 mg/day of NMN or NR approximately doubled whole-blood NAD+ after 14 days of supplementation. Nicotinamide only raised NAD+ acutely (at 4 hours post-dose) and did not sustain the increase. The study also found evidence that gut bacteria convert both NMN and NR into nicotinic acid, which then becomes a potent NAD+ booster. That finding complicates the "direct uptake" narrative both supplement camps have pushed.

Oral precursors appear well tolerated in the short term. Across 33 human intervention studies reviewed in the 2026 PRISMA systematic review (Gallagher & Emmanuel, 2026, Ageing Research Reviews), oral NR and NMN were generally well tolerated over treatment periods of weeks to months. Short-term human studies have generally reported NMN and NR to be well tolerated, with no major safety concerns identified during the study periods. Long-term safety remains less well established. A 2026 meta-analysis focused on NMN reported similar short-term findings (Yang et al., 2026). For a full rundown, see NMN side effects.

Who should be cautious with NMN or NR?

Human safety data for NMN and NR are still relatively limited, particularly for long-term use and for certain groups. Talk with a healthcare professional before taking an NAD+ precursor if you are pregnant or breastfeeding, are under 18, have significant liver or kidney disease, have cancer or are undergoing cancer treatment, or take multiple medications.

Which NAD+ benefits show promise but aren't proven?

Exercise capacity, insulin sensitivity, and sleep show early signals in human NMN or NR trials, but none is proven. Exercise results were non-significant trends, the positive insulin trial wasn't backed by a 2024 meta-analysis of glucose and lipids, the sleep data come from one small trial, and muscle preservation in adults over 60 hasn't held up.

Exercise capacity. A 2024 systematic review of 10 NMN randomized controlled trials (437 total participants) found non-significant improvements in grip strength and other physical performance markers at doses of 150–1,200 mg/day over an average of 9.6 weeks. "Non-significant" means the trend pointed in the right direction but wasn't strong enough to rule out chance.

Insulin sensitivity. The first major NMN human trial, published by Yoshino et al. in Science (2021), reported improved skeletal muscle insulin signaling in overweight postmenopausal women taking 250 mg/day NMN for 10 weeks. However, a 2024 meta-analysis of 12 NMN RCTs with 513 total participants found no significant effect on fasting glucose, triglycerides, total cholesterol, LDL-C, or HDL-C (Zhang et al., Critical Reviews in Food Science and Nutrition). The authors explicitly warned that "an exaggeration of the benefits of NMN supplementation may exist in the field."

Muscle results have been flat too. A 2025 meta-analysis found NMN and NR did not preserve muscle mass or function in adults over 60 (Prokopidis et al., 2025).

Sleep and fatigue. One 12-week RCT found that 250 mg/day NMN improved afternoon drowsiness and sleep quality in older adults, with time-dependent effects. This is a single study with a small sample.

Which NAD+ benefits have only been shown in rodents?

Anti-aging effects, cognitive protection, cardiovascular benefits, and fertility improvements have so far been shown only in mice or rats. The 2026 PRISMA review identified 80 rodent studies showing improvements in metabolic, mitochondrial, inflammatory, and functional outcomes, though results varied by model and endpoint. The gap between rodent results and human outcomes remains wide and humbling.

Mice that received NMN at equivalent human doses showed dramatic improvements that simply haven't replicated at the same magnitude in people.

The 2025 review in Nature Metabolism (Vinten et al.) put it directly: "Although preclinical studies support the idea that supplementation with NAD+ precursors is a promising therapeutic strategy to promote healthy ageing, human clinical trials have shown limited efficacy."

Is NAD+ Good for You?

Yes. NAD+ is essential, since every cell needs it to make energy and repair DNA, and cells die without it. The more practical question is whether supplements help. Oral precursors like NMN and NR reliably raise blood NAD+, but trials haven't consistently shown benefits people can feel, such as more energy or better sleep.

The more useful question is whether supplementing NAD+ precursors helps. Based on the evidence available in September 2026, here's an honest summary:

If you take an oral NAD+ precursor like NMN or NR, your blood NAD+ levels will go up. That part is reliable and well-documented. Whether that increase translates into outcomes you can feel (more energy, better sleep, sharper thinking, slower aging) is where the science gets murky. Some people report subjective improvements. Clinical trials have not consistently confirmed those reports at a population level.

The March 2026 expert review in Nature Aging, authored by over 25 scientists from the University of Oslo, Akershus University Hospital, and international collaborators, highlighted NAD+ as a serious research target for Alzheimer's and Parkinson's disease. But "serious research target" is not the same as "proven treatment." The NADage Study (NCT06208527), a large randomized double-blind trial of NR for age-related functional decline, is currently recruiting in Norway and won't report primary results until 2027 at the earliest.

Supplementing NAD+ precursors is not dangerous for most adults based on current evidence. It's also not a magic pill. That's the boring, accurate answer.

What Is the Difference Between NAD+ and NADH?

NAD+ and NADH are the same molecule in two different states. NAD+ is the oxidized form, meaning it's missing two electrons and a hydrogen ion. NADH is the reduced form: it has picked up those electrons and hydrogen. When your mitochondria break down glucose or fat, NAD+ accepts electrons and becomes NADH.

That NADH then donates its electrons to the electron transport chain, regenerating NAD+ and producing ATP in the process.

This cycle repeats continuously. Your cells maintain a ratio of NAD+ to NADH that affects metabolic rate, oxidative stress, and gene expression. A higher ratio (more NAD+ relative to NADH) generally signals that cells are in an active, energy-producing state. A lower ratio can indicate metabolic stress.

Some supplement brands sell NADH directly, marketing it as a "pre-made" energy molecule. The problem is delivery. NADH is unstable in the digestive tract, breaks down rapidly in stomach acid, and has poor oral bioavailability compared to NAD+ precursors like NMN or NR. Most researchers studying NAD+ restoration in humans use precursors, not NADH, for that reason.

How Does Your Body Make NAD+?

Your body makes NAD+ through three pathways. The de novo pathway builds it from the amino acid tryptophan, mainly in the liver and kidneys. The Preiss-Handler pathway converts niacin (nicotinic acid). The salvage pathway recycles nicotinamide back into NMN and then NAD+, and it supplies most of your daily NAD+.

The de novo pathway (from tryptophan)

This is the "from scratch" route. Your body takes the amino acid tryptophan (found in turkey, eggs, cheese, and other protein sources) and converts it through a long chain of reactions called the kynurenine pathway. This pathway produces a small amount of NAD+ but is mainly active in the liver and kidneys. It's slow, requires eight enzymatic steps, and is not the primary source of daily NAD+ in most tissues.

The Preiss-Handler pathway (from niacin/nicotinic acid)

Nicotinic acid (niacin, one form of vitamin B3) enters this three-step pathway and gets converted into NAD+ through an intermediate called NAAD. This pathway gained new attention in 2026 when the head-to-head precursor trial found that gut bacteria convert both NMN and NR into nicotinic acid, which then feeds this pathway. If that result holds up, the Preiss-Handler pathway may be more important for oral NAD+ supplementation than anyone previously thought.

The salvage pathway (from nicotinamide)

This is the workhorse. When sirtuins, PARPs, or CD38 consume NAD+, they release nicotinamide (NAM) as a byproduct. The enzyme NAMPT recycles that nicotinamide back into NMN, and then NMNAT enzymes convert NMN into NAD+. This loop runs continuously in every tissue and accounts for the majority of your daily NAD+ production. NAMPT is the bottleneck: it's the slowest step, and its expression declines with age. That's one reason NAD+ levels fall over time, because the recycling engine loses capacity.

Where do NMN and NR supplements fit? NMN enters the salvage pathway one step past the NAMPT bottleneck, feeding directly into the NMNAT conversion to NAD+. NR enters one step before NMN: NR kinases phosphorylate NR into NMN, which then becomes NAD+. Both skip the rate-limiting NAMPT step, which is the theoretical basis for why supplementing either one can raise NAD+ levels even when NAMPT activity has declined.

Is NAD+ a Vitamin?

No. NAD+ is made from vitamins, but it is not itself a vitamin. The distinction matters because vitamins are essential nutrients your body cannot manufacture in sufficient quantities, so you must get them from food. Your body does manufacture NAD+, using vitamin B3 (in its various forms) as the raw material.

The confusion comes from the fact that severe niacin deficiency causes pellagra, a disease whose symptoms (dermatitis, diarrhea, dementia) result from collapsing NAD+ levels. In that sense, the link between B3 and NAD+ has been known for almost a century. But healthy adults with adequate B3 intake still experience NAD+ decline with age, because the decline is driven by increased consumption (CD38, PARP) rather than insufficient dietary B3.

This is why simply eating more niacin-rich foods or taking a B3 supplement does not reliably reverse age-related NAD+ decline. You need enough B3 to avoid deficiency, certainly. But the age-related NAD+ problem is a supply-vs-demand imbalance, not a B3 shortage.

NAD+ and Energy: What's Actually Happening?

NAD+ is required for energy production: your mitochondria need it to accept and shuttle electrons from glucose, and without it ATP output drops. That's why "NAD+ gives you energy" is such a common marketing claim. It holds at the cellular level, but raising NAD+ with supplements hasn't been shown to reliably make people feel more energetic.

The true part: NAD+ is required for ATP production. Every molecule of glucose your mitochondria process requires NAD+ to accept and shuttle electrons. Without NAD+, the electron transport chain stalls and ATP output drops. That's basic biochemistry.

The misleading part: taking an NAD+ precursor does not work like caffeine. It doesn't stimulate your nervous system. It doesn't give you a jolt. What it does, in theory, is restore a depleted cofactor so your mitochondria can run at normal capacity. If your NAD+ levels are genuinely low and limiting your mitochondrial function, restoring them could improve cellular energy production. But you wouldn't feel that as a burst of alertness. You might feel it as slightly less fatigue, slightly better exercise recovery, or slightly more stamina over weeks. Or you might not feel anything at all.

The 2024 systematic review of NMN trials noted that some studies found improvements in afternoon drowsiness and reduced fatigue scores, but the effect sizes were small and not all trials measured subjective energy. People who report feeling "more energetic" after starting NAD+ precursors may be experiencing real improvements, placebo effects, or both. The clinical data does not yet distinguish between these possibilities at a population level.

How Can You Raise NAD+ Levels?

Four approaches can raise NAD+ levels, listed here from most to least studied in humans: oral precursors such as NMN or NR, which approximately doubled whole-blood NAD+ after 14 days in a 2026 trial; regular exercise, which boosts the NAMPT enzyme; caloric restriction and fasting; and CD38 inhibition, which targets the main enzyme that consumes NAD+ with age.

1. Oral NAD+ precursor supplements (NMN or NR)

This is the most direct route and the one with the most clinical data. Both NMN and NR have been shown in multiple human trials to elevate blood NAD+ levels within days to weeks. Typical research doses range from 250 mg to 1,000 mg per day for NMN and 300 mg to 1,000 mg per day for NR.

The January 2026 Nestlé trial (Christen et al., 65 participants) found no significant difference between NMN and NR in their ability to raise NAD+. At 1,000 mg/day, both approximately doubled whole-blood NAD+ after 14 days. The authors identified a shared mechanism: gut bacteria convert both compounds into nicotinic acid, which then feeds the Preiss-Handler biosynthesis pathway to produce NAD+. Separate 2025 work in Science Advances showed that orally taken NR and NMN drive NAD+ synthesis through enterohepatic circulation, the recycling loop between gut and liver (Yaku et al., 2025).

A second 2026 trial complicates that tidy picture. Berven and colleagues at Haukeland University Hospital in Norway ran a pharmacokinetic study measuring NAD+ in both blood and brain, and found NR raised blood NAD+ substantially more than NMN (roughly 161% versus 69% over the treatment period). Neither precursor raised brain NAD+ after 8 days, though NR did after 4 weeks in healthy participants. So the "NMN and NR are equivalent" conclusion depends heavily on study design and what you measure. The honest current state: both raise blood NAD+, the magnitude is still debated, and whether either reaches the tissues that matter most (brain, muscle) is far from settled.

2. Exercise

Physical activity increases NAMPT expression, the rate-limiting enzyme in NAD+ biosynthesis. Aerobic exercise in particular has been associated with elevated NAD+ levels in skeletal muscle, though the magnitude varies by study, exercise type, and fitness level. Exercise also activates AMPK, which upregulates NAD+ synthesis. But you can't "exercise your way" to the same NAD+ levels you had at 25. The effect helps but doesn't fully offset age-related decline.

3. Caloric restriction and fasting

Reduced calorie intake activates AMPK and upregulates NAMPT, both of which increase NAD+ production. This is the original mechanism by which caloric restriction was linked to longevity in animal models. Intermittent fasting may offer some of the same NAD+ benefits, though human data is limited and confounded by other metabolic changes that happen during fasting.

4. CD38 inhibition

Since CD38 is the primary NAD+ consumer that increases with age, blocking it is a logical target. The flavonoid apigenin (found in parsley, celery, and chamomile) inhibits CD38 in cell and animal studies. Quercetin and luteolin have shown similar effects in preclinical work. No human clinical trial has yet tested CD38 inhibitors specifically for NAD+ elevation, but several are in planning stages as of 2026. The logic is straightforward: if CD38 is the biggest drain on your NAD+ pool, and if its expression rises with age-related inflammation, then blocking CD38 could slow the drain at its source rather than just pouring more precursor into a leaking system. Some researchers have proposed combining a CD38 inhibitor with an NAD+ precursor to get both sides of the equation, reducing consumption while boosting production. That combination has not been tested in humans, but it represents a direction several labs are actively pursuing. The challenge is that CD38 also plays roles in immune signaling and calcium metabolism, so completely shutting it down carries risks that need careful evaluation in clinical settings.

Watch: a pharmacist reviews NMN, the most-used NAD+ precursor

Heather Dickson, PharmD, a residency-trained clinical pharmacist, walks through what NMN does to NAD+ levels, what the human research shows so far, and the safety questions and drug interactions worth raising with your doctor. The video is from the YourHealthier YouTube channel.

Does NAD+ Decline Cause Aging?

No one knows yet whether NAD+ decline causes aging. NAD+ falls with age in some human tissues, and restoring it in aged mice reverses several hallmarks of aging, including mitochondrial dysfunction and DNA damage. Researchers also have a plausible mechanism involving CD38 and sirtuins. Still, correlation plus a mechanism isn't proof, and causation in humans hasn't been shown.

What we know is that NAD+ decline correlates with aging and that restoring NAD+ in aged mice reverses several hallmarks of aging: mitochondrial dysfunction, DNA damage accumulation, inflammatory signaling, and metabolic decline. The Camacho-Pereira and Covarrubias papers established a plausible causal mechanism (CD38 → NAD+ depletion → sirtuin/PARP dysfunction). Gomes et al. (2013) showed that declining nuclear NAD+ induces a pseudohypoxic state through HIF-1α stabilization, disrupting communication between the nucleus and mitochondria. That process that could be reversed by raising NAD+ levels.

But correlation plus a mechanism doesn't equal causation. NAD+ decline could be a cause, a consequence, or a bystander in human aging. A 2026 computational model published in PMC proposed that age-associated NAD+ depletion shifts cells from oxidative phosphorylation toward glycolysis, a metabolic pattern also seen in cancer, suggesting NAD+ decline may create conditions that favor tumor development in older adults. If confirmed, this would add urgency to NAD+ restoration research. But the model is theoretical and awaits experimental validation.

The best current framing: NAD+ decline is not itself one of the twelve hallmarks of aging in the López-Otín et al., 2023 update, but it connects to several of them. Mitochondrial dysfunction, genomic instability, cellular senescence, and deregulated nutrient sensing all connect back to NAD+ levels in published models. That makes it an unusually interesting therapeutic target, even if we can't yet prove it's a root cause. Most interventions in aging research target one hallmark at a time. NAD+ restoration, at least in theory, touches four or five at once. That's why the field has attracted so much funding and attention, and it's why the gap between the excitement and the hard clinical evidence matters so much.

What's New in NAD+ Research (2025–2026)?

Three NAD+ research developments stand out from 2025 and 2026: the first head-to-head human trial of NMN, NR, and NAM, which found gut bacteria drive much of the NAD+ rise; a PRISMA systematic review of 113 studies showing precursors raise NAD+ safely but with inconsistent clinical benefits; and a Nature Aging review on NAD+ and neurodegeneration.

The first head-to-head human trial of NMN vs NR vs NAM. Published in early 2026, this study ended years of speculation by directly comparing the three most common NAD+ precursors in the same trial. The finding that gut bacteria mediate NAD+ elevation from both NMN and NR through nicotinic acid conversion was unexpected and challenges the mechanistic stories both the NMN and NR camps have told.

The 2026 PRISMA systematic review. Gallagher and Emmanuel reviewed 113 eligible studies (33 human, 80 rodent) and delivered a reality check: in humans, NAD+ precursors consistently raise NAD+ and appear safe, but effects on healthspan-relevant clinical outcomes remain inconsistent. No published trial has tested IV NAD+ for anti-aging in a controlled setting. This review is now the most complete synthesis of the NAD+ supplementation evidence base.

The Nature Aging expert review on NAD+ and neurodegeneration. Published in March 2026 by a consortium of 25+ scientists, this review highlighted NAD+ as a research priority for Alzheimer's and Parkinson's disease, citing evidence that NAD+ depletion accelerates neuronal death in both conditions. The NADage trial in Norway and several smaller trials in Japan and the U.S. are testing whether NAD+ precursors can slow cognitive decline in aging populations.

Frequently Asked Questions

What does NAD+ do for your body?

NAD+ does three core jobs in your body. It carries electrons to produce ATP, the energy currency of your cells. It activates sirtuins, which regulate gene expression and inflammation. And it fuels PARP enzymes that repair DNA damage. More than 500 enzymatic reactions across every cell type depend on it.

What does NAD stand for?

NAD stands for nicotinamide adenine dinucleotide, a coenzyme found in every living cell. The plus sign in NAD+ marks its oxidized, electron-accepting form. When NAD+ picks up electrons during metabolism, it becomes NADH, and the two forms cycle back and forth as your cells produce energy.

Is NAD+ the same as vitamin B3?

No. NAD+ and vitamin B3 are different molecules. Vitamin B3, in the form of nicotinamide, niacin, or nicotinamide riboside, is a precursor your body converts into NAD+ through several enzymatic steps. Getting enough B3 supports NAD+ production, but the vitamin itself isn't the coenzyme your cells use.

What is NAD+ used for?

In research, NAD+ precursors (NMN and NR) are studied for their potential effects on aging, metabolic function, DNA repair, and neurodegeneration. As supplements, people take them with the goal of restoring age-related NAD+ decline, though clinical outcomes beyond raising blood NAD+ levels remain unproven in large trials.

Is NAD+ good for you?

NAD+ is essential for life. Every cell needs it. Supplementing with NAD+ precursors is generally well tolerated in short-term trials, though long-term safety is less established. It reliably raises blood NAD+ levels. Whether that translates into measurable health improvements for the average person is still being studied.

How much does NAD+ decline with age?

There's no single answer. Studies have found lower NAD+ with age in skin (Massudi et al., 2012; 49 people from newborns to age 77) and in plasma (Clement et al., 2019; healthy adults aged 20 to 87), but a 2026 study across seven cohorts found whole-blood NAD+ stable with age (Trętowicz et al., 2026).

NAD+ changes appear to differ by tissue and measurement method, so a single figure like "50% by age 60" isn't supported.

What is the difference between NAD+ and NMN?

NAD+ is the molecule your cells use. NMN (nicotinamide mononucleotide) is a precursor, a building block your body converts into NAD+. When you take an NMN supplement, your body uses it to manufacture NAD+. You can't take NAD+ directly by mouth because it breaks down in the gut before reaching cells.

What is the difference between NAD+ and NADH?

NAD+ and NADH are the same molecule in two states. NAD+ is the oxidized form (ready to accept electrons). NADH is the reduced form (carrying electrons). They cycle back and forth during energy production. Most NAD+ research and supplementation focuses on the NAD+ form because sirtuin and PARP enzymes specifically require NAD+, not NADH.

What is NAD+ used for in medicine?

Clinically, NAD+ is administered intravenously at some wellness clinics for addiction recovery, chronic fatigue, and anti-aging. However, as of 2026, no IV NAD+ protocol has been tested in a published randomized controlled trial for any of these indications. The PRISMA systematic review found zero eligible outcomes trials evaluating IV or intramuscular NAD+ for anti-aging or wellness.

Most clinical research focuses on oral precursors (NMN and NR), not direct NAD+ infusion.

Is NAD good for men specifically?

NAD+ isn't specifically better for men, because it functions identically in male and female biology. Some rodent studies have explored NAD+ precursors for testosterone-related pathways, but no human trial has demonstrated sex-specific benefits. Human data on sex differences in NAD+ with age are limited.

Does NAD+ help with weight loss?

In mice, NAD+ restoration has improved metabolic function and reduced fat accumulation. In humans, meta-analyses of NMN trials have not shown statistically significant effects on body weight, BMI, or lipid profiles as of 2026. The animal data is encouraging; the human data isn't there yet.

Why is NAD+ important?

NAD+ sits at the intersection of energy production, DNA repair, and gene regulation. It's one of the few molecules that participates in all three processes simultaneously. Where it declines with age, that decline can affect mitochondrial function, genomic stability, and inflammatory control, which is why researchers link it to several of the twelve recognized hallmarks of aging.

Can you get NAD+ from food?

You can get NAD+ precursors from food, not NAD+ itself. Foods rich in niacin (vitamin B3) include chicken, turkey, tuna, salmon, peanuts, and mushrooms. Tryptophan-rich foods (eggs, cheese, turkey) also contribute through the de novo pathway. Trace amounts of NMN have been detected in edamame, broccoli, avocado, and cucumber, but the quantities are far below what clinical trials use.

You'd need to eat roughly 50 to 100 kg of broccoli per day to match a 250 mg NMN supplement dose.

How long does it take for NAD+ supplements to work?

Blood NAD+ levels typically rise within days. The January 2026 head-to-head trial measured significant increases by day 14 for both NMN and NR. Whether subjective benefits (energy, sleep, exercise recovery) follow is less predictable. Clinical trials that reported improvements in sleep and physical performance ran for 8 to 12 weeks.

If you're going to try an NAD+ precursor, giving it at least two to three months before evaluating is reasonable based on the trial timelines used in published research.

Related Reading

• Is NAD+ a Peptide? No. Here's What It Actually Is
• NAD+ Side Effects: What Clinical Trials Report
• NAD+ Dosage: Oral, Injection & IV Dosing Guide
• NAD+ Patches: Do They Work?
• NAD+ Nasal Spray: Does It Work?
• NMN vs NAD: What's the Difference?
• Best NAD+ Supplements in 2026
• NAD+ Supplements: Types, Evidence & How to Choose
• NAD+ IV Therapy: How It Works, Costs & Evidence
• NAD+ Injections: Benefits, Side Effects & Cost
• What Is NMN? Benefits, NAD+ & Aging Research
• Best NMN Supplements in 2026

Authoritative Resources

• Cleveland Clinic: NAD (Nicotinamide Adenine Dinucleotide)
• Nature Metabolism: NAD+ Precursor Supplementation in Human Ageing (2025)
• Ageing Research Reviews: NAD+ Supplementation PRISMA Systematic Review (2026)

References

1. Amjad S, Nisar S, Bhat AA, et al. Role of NAD+ in regulating cellular and metabolic signaling pathways. Molecular Metabolism. 2021;49:101195. doi:10.1016/j.molmet.2021.101195 View source (PubMed)
2. Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism. 2016;23(6):1127–1139. doi:10.1016/j.cmet.2016.05.006 View source (PubMed)
3. Covarrubias AJ, Kale A, Perrone R, et al. Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages. Nature Metabolism. 2020;2(11):1265–1283. doi:10.1038/s42255-020-00305-3 View source (PubMed)
4. Peluso A, Damgaard MV, Mori MAS, Treebak JT. Age-dependent decline of NAD+: universal truth or confounded consensus? Nutrients. 2022;14(1):101. doi:10.3390/nu14010101 View source (PubMed)
5. Trętowicz MM, Scantlebery AML, Schomakers BV, et al. Human whole-blood NAD+ levels do not vary with age or lifestyle interventions. Nature Metabolism. 2026;8(6):1282–1290. doi:10.1038/s42255-026-01537-5 View source (PubMed)
6. Massudi H, Grant R, Braidy N, et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS ONE. 2012;7(7):e42357. doi:10.1371/journal.pone.0042357 View source (PubMed)
7. Clement J, Wong M, Poljak A, et al. The plasma NAD+ metabolome is dysregulated in "normal" aging. Rejuvenation Research. 2019;22(2):121–130. doi:10.1089/rej.2018.2077 View source (PubMed)
8. Gomes AP, Price NL, Ling AJ, et al. Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155(7):1624–1638. doi:10.1016/j.cell.2013.11.037 View source (PubMed)
9. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224–1229. doi:10.1126/science.abe9985 View source (PubMed)
10. Zhang J, Poon ETC, Wong SHS. Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis. Critical Reviews in Food Science and Nutrition. 2025;65(22):4382–4400. doi:10.1080/10408398.2024.2387324 View source (PubMed)
11. Gallagher C, Emmanuel OO. NAD+ supplementation for anti-aging and wellness: a PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews. 2026;116:103057. doi:10.1016/j.arr.2026.103057 View source (PubMed)
12. Vinten KT, Trętowicz MM, Coskun E, et al. NAD+ precursor supplementation in human ageing: clinical evidence and challenges. Nature Metabolism. 2025;7(10):1974–1990. doi:10.1038/s42255-025-01387-7 View source (PubMed)
13. López-Otín C, Blasco MA, Partridge L, et al. Hallmarks of aging: an expanding universe. Cell. 2023;186(2):243–278. doi:10.1016/j.cell.2022.11.001 View source (PubMed)
14. Yaku K, Nakagawa T. NAD+ precursors in human health and disease: current status and future prospects. Antioxidants & Redox Signaling. 2023;39(16-18):1133–1149. doi:10.1089/ars.2023.0354 View source (PubMed)
15. Chini CCS, Cordeiro HS, Tran NLK, Chini EN. NAD metabolism: role in senescence regulation and aging. Aging Cell. 2024;23(1):e13920. doi:10.1111/acel.13920 View source (PubMed)
16. Christen S, Redeuil K, Goulet L, et al. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nature Metabolism. 2026;8:62–73. doi:10.1038/s42255-025-01421-8 View source (PubMed)
17. Berven H, Svensen M, Eikeland H, et al. The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation. iScience. 2026;29(3):114764. doi:10.1016/j.isci.2026.114764 View source (PubMed)

Written by Tao Wu. Last reviewed September 2026. This article is for informational purposes and does not constitute medical advice. Talk to your doctor before starting any new supplement.

NAD+ Supplements: What Human Trials Show

Metric	Value
Blood NAD+ after 14 days of NMN or NR	~2x baseline
Nicotinamide (NAM), 14 days	no sustained rise
Human studies in 2026 safety review	33, well tolerated short term
NMN effect on glucose and lipids	none significant (12 RCTs)
NMN or NR on muscle, adults 60+	no benefit found
Main NAD+-consuming enzymes	sirtuins, PARPs, CD38
Source: YourHealthier · Christen et al. 2026 (Nat Metab); Gallagher & Emmanuel 2026; Zhang et al. 2024; Prokopidis et al. 2025

Chart: NAD+ Supplements: What Human Trials Show. Data: blood NAD+ roughly doubled after 14 days of NMN or NR; nicotinamide produced no sustained rise; a 2026 review of 33 human studies found NMN and NR generally well tolerated in the short term; a meta-analysis of 12 NMN trials found no significant effect on glucose or lipids; a 2025 meta-analysis found no muscle benefit in adults over 60; sirtuins, PARPs, and CD38 are the main enzymes that consume NAD+. Sources: Christen et al. 2026, Nature Metabolism; Gallagher & Emmanuel 2026, Ageing Research Reviews; Zhang et al. 2024, Critical Reviews in Food Science and Nutrition; Prokopidis et al. 2025, Journal of Cachexia, Sarcopenia and Muscle. yourhealthier.com